Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan · Delayed Price · Currency is TWD 208.50
-3.50 (-1.65%)
At close: Mar 26, 2026
Lotus Pharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 4,720 | 5,066 | 4,106 | 3,021 | 1,403 |
Depreciation & Amortization | 1,526 | 1,273 | 1,200 | 926.96 | 748.76 |
Other Amortization | 9.42 | 10.13 | 10.23 | 9.91 | 10.62 |
Loss (Gain) From Sale of Assets | 13.72 | 0.7 | 24.75 | -2.52 | 3.2 |
Asset Writedown & Restructuring Costs | 303.02 | 159.99 | 179.37 | 136.67 | 234.82 |
Loss (Gain) From Sale of Investments | -548.28 | -604.16 | -715.05 | -286.81 | - |
Stock-Based Compensation | 279.38 | 348.65 | 106.49 | 39.41 | 57.66 |
Provision & Write-off of Bad Debts | -7.61 | -2.96 | -4.04 | -3.33 | 34.24 |
Other Operating Activities | -572.03 | 615.83 | 144.35 | 788.08 | 460.19 |
Change in Accounts Receivable | 2,156 | -850.77 | -1,665 | -1,373 | -633.42 |
Change in Inventory | -447.43 | -181.33 | -623.18 | -313.29 | -1,125 |
Change in Accounts Payable | -127.59 | 346.45 | -659.57 | 648.39 | -980.98 |
Change in Unearned Revenue | -10.78 | 32.93 | -69.33 | 20 | -9.74 |
Change in Other Net Operating Assets | 188.33 | -59.23 | -420.87 | 108.67 | -83.63 |
Operating Cash Flow | 7,482 | 6,155 | 1,614 | 3,719 | 119.66 |
Operating Cash Flow Growth | 21.56% | 281.29% | -56.60% | 3008.27% | -93.86% |
Capital Expenditures | -1,320 | -353.84 | -410.57 | -577.16 | -572.73 |
Sale of Property, Plant & Equipment | 0.16 | 0.61 | 1.25 | 9.38 | 0.11 |
Cash Acquisitions | -8,134 | -1,242 | - | - | - |
Sale (Purchase) of Intangibles | -3,033 | -1,112 | -2,864 | -2,492 | -1,043 |
Investment in Securities | - | - | - | -1,583 | - |
Other Investing Activities | 19.21 | 15.82 | 24.48 | -13.38 | 38.8 |
Investing Cash Flow | -12,468 | -2,691 | -3,249 | -4,656 | -1,577 |
Short-Term Debt Issued | 3,900 | 2,378 | 1,216 | 1,435 | 1,291 |
Long-Term Debt Issued | 21,722 | 2,951 | 20,476 | 6,250 | 5,063 |
Total Debt Issued | 25,622 | 5,328 | 21,692 | 7,685 | 6,354 |
Short-Term Debt Repaid | -4,004 | -1,260 | -861.82 | -2,100 | -870.8 |
Long-Term Debt Repaid | -12,428 | -2,123 | -18,522 | -3,259 | -5,642 |
Total Debt Repaid | -16,432 | -3,382 | -19,384 | -5,359 | -6,513 |
Net Debt Issued (Repaid) | 9,190 | 1,946 | 2,308 | 2,326 | -159.41 |
Issuance of Common Stock | 6.77 | 0.26 | 0.6 | - | 1,414 |
Repurchase of Common Stock | -780.99 | - | - | - | -57.35 |
Common Dividends Paid | -1,520 | -1,232 | -906.23 | -506.06 | -92.01 |
Other Financing Activities | - | -0.31 | - | -558.27 | 558.31 |
Financing Cash Flow | 6,896 | 714.09 | 1,403 | 1,262 | 1,663 |
Foreign Exchange Rate Adjustments | -200.73 | 81 | 19.91 | 52.89 | -89.52 |
Net Cash Flow | 1,710 | 4,259 | -212.5 | 377.89 | 116.49 |
Free Cash Flow | 6,162 | 5,801 | 1,204 | 3,142 | -453.07 |
Free Cash Flow Growth | 6.23% | 381.96% | -61.70% | - | - |
Free Cash Flow Margin | 30.05% | 31.21% | 7.10% | 21.47% | -3.58% |
Free Cash Flow Per Share | 23.55 | 22.02 | 4.59 | 12.01 | -1.76 |
Cash Interest Paid | 1,107 | 495.06 | 446.25 | 290.7 | 227.93 |
Cash Income Tax Paid | 1,301 | 915.24 | 1,036 | 444.89 | 259.57 |
Levered Free Cash Flow | 3,368 | 3,200 | -4,296 | 1,917 | -1,801 |
Unlevered Free Cash Flow | 3,916 | 3,551 | -3,963 | 2,139 | -1,634 |
Change in Working Capital | 1,758 | -711.95 | -3,438 | -909.7 | -2,833 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.